Antitumor Effect of Paclitaxel-Loaded PEGylated Immunoliposomes Against Human Breast Cancer Cells
- 901 Downloads
The antitumor effect of paclitaxel-loaded PEGylated immunoliposome (PILs) was investigated in breast cancer cell lines and the xenograft model.
Herceptin was conjugated to paclitaxel-loaded PEGylated liposomes (PLs). In vitro cellular uptake and cytotoxicity of PILs were determined in breast cancer cell lines while in vivo antitumor efficacy was evaluated in the xenograft nude mouse model.
The PILs formulation was able to significantly increase the HER2 mediated cellular uptake of paclitaxel compared to the PLs in cell lines overexpressing HER2 (BT-474 and SK-BR-3 cells). However, in the MDA-MB-231 cells, which express low levels of HER2, the difference between the PILs and PLs formulation was not significant. The biological activity of Herceptin was maintained throughout the conjugation process as exhibited by the antitumor dose–response curves determined for Herceptin itself, for the thiolated Herceptin alone and subsequently for the immunoliposome-coupled Herceptin. In BT-474 and SK-BR-3 cells, the cytotoxicity of the PILs was more potent than that of Taxol. Moreover, in in vivo studies, PILs showed significantly higher tumor tissue distribution of paclitaxel in the BT-474 xenograft model and more superior antitumor efficacy compared to Taxol and PLs. However, in the MDA-MB-231 xenograft model, PILs and PLs showed similar tumor tissue distribution as well as antitumor activity.
These results suggest that HER2-mediated endocytosis is involved in the PILs formulation. The ability of the PILs formulation to efficiently and specifically deliver paclitaxel to the HER2-overexpressing cancer cells implies that it is a promising strategy for tumor-specific therapy for HER2-overexpressing breast cancers.
Key wordsantitumor effect herceptin paclitaxel PEGylated immunoliposome
Dulbecco’s modified eagle medium
enhanced permeability and retention
fetal bovine serum
human epidermal growth factor receptor-2
minimum essential medium
3-(4,5-dimethylthiazol-2-ly)– 2,5-diphenyl-tetrazolium bromide
This research was financially supported by the Ministry of Science and Technology (M10528010004-06N2801-00410) in Korea. The authors would like to thank the Lipoid GmbH (Germany) and Genentech companies for providing phosphatidylcholine and Herceptin, respectively.
- 8.J. Baselga, D. Tripathy, J. Mendelsohn, S. Baughman, C. C. Benz, L. Dantis, N. T. Sklarin, A. D. Seidman, C. A. Hudis, J. Moore, P. P. Rosen, T. Twaddell, I. C. Henderson, and L. Norton. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER/neu-overexpressing metastatic breast cancer. J. Clin. Oncol. 14:737–744 (1996).PubMedGoogle Scholar
- 9.M. A. Cobleigh, C. L. Vogel, D. Tripathy, N. J. Robert, S. Scholl, L. Fehrenbacher, J. M. Wolter, V. Paton, S. Shak, G. Lieberman, and D. J. Slamon. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in woman who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J. Clin. Oncol. 17:2639–2648 (1999).PubMedGoogle Scholar
- 10.D. J. Slamon, B. Leyland-Jones, S. Shak, H. Fuchs, V. Paton, A. Bajamonde, T. Fleming, W. Eiermann, J. Wolter, M. Pegram, J. Baselga, and L. Norton. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cnacer that overexpresses HER2. N. Engl. J. Med. 344:783–792 (2001).PubMedCrossRefGoogle Scholar
- 13.A. M. Yvon, P. Wadsworth, and M. A. Jordan. Taxol suppresses dynamics of individual microtubules in living human tumor cells. Mol. Bio. Cell 10:947–959 (1999).Google Scholar
- 18.S. Suzuki, S. Watanabe, T. Masuko, and Y. Hashimoto. Preparation of long-circulating immunoliposomes containing adriamycin by a novel method to coat immunoliposomes with polyethylene glycol. Biochem. Biophys. Acta 1245:22–29 (1995).Google Scholar
- 21.K. R. Reddy. Controlled-release, pegylation, liposomal formulation: new mechanisms in the delivery of injectable drugs. Drug Deliv. 34:915–923 (2000).Google Scholar
- 27.U. B. Nielsen, D. B. Kirpotin, E. M. Pickering, K. Hong, J. W. Park, M. R. Shalaby, Y. Shao, C. C. Benz, and J. D. Marks. Therapeutic efficacy of anti-ErbB2 immnoliposomes targeted by a phage antibody selected for cellular endocytosis. Biochim. Biophys. Acta 1591:109–118 (2002).PubMedCrossRefGoogle Scholar